Related Experiment Videos
Central venous lines in haemophilia
1Department of Paediatrics, Lund University, University Hospital, Malmö, Sweden. Rolf.Ljung@pediatrik.mas.lu.se
Summary
Central venous access devices in haemophilia patients have frequent complications, primarily infections and technical issues. Careful consideration of patient factors and aseptic techniques can help reduce these risks.
Area of Science:
- Medical Devices
- Haematology
- Infectious Diseases
Background:
- Implantable central venous access devices (CVADs) are crucial for haemophilia patients.
- Complications associated with CVADs, including infections and thrombosis, require careful management.
Purpose of the Study:
- To review the complications of central venous access devices in haemophilia patients.
- To provide insights into infection rates and thrombosis risks.
- To guide clinical decision-making regarding CVAD use.
Main Methods:
- Literature review of studies on CVAD use in haemophilia.
- Analysis of reported infection rates in non-inhibitor and inhibitor patients.
- Evaluation of thrombosis data from available series.
Main Results:
- Infections are the most frequent complication, with varying rates in non-inhibitor patients (0.2-1.0 per 1000 days) and higher rates in inhibitor patients (approx. 1 per 6-12 months).
- Clinically apparent thrombosis is infrequent, but venogram studies show varied results regarding abnormalities.
- Decision to use CVADs should balance medical goals with bleeding tendency, social factors, and center-specific risks.
Conclusions:
- Infections and technical issues are primary concerns with CVADs in haemophilia.
- Risk assessment and stringent aseptic measures, surveillance, and user education are vital for minimizing complications.
- Individualized patient assessment is crucial for safe and effective CVAD utilization.